GlassScriptPhysician profile
Sherry Roberts
NPI 1023387933
$5,009.15
in general payments reported to CMS, 2019-2025
19 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $920 · 2023: $1,716 · 2024: $1,085 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,772 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,771.57 |
| Education | $215.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.55 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $621.91 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $561.96 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Corium, LLC | $512.26 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $394.84 | 2022-2024 | Spravato |
| Axsome Therapeutics, INC. | $361.25 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $322.14 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $222.24 | 2021-2025 | Ingrezza |
| Tris Pharma INC | $212.97 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $212.54 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $134.92 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $113.16 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $73.39 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $64.18 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.53 | 2024-2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.82 | 2022-2024 | Quviviq |
| Validus Pharmaceuticals LLC | $18.02 | 2023 | Equetro |
| Supernus Pharmaceuticals, INC. | $17.39 | 2023 | Qelbree |
| Almatica Pharma LLC | $16.08 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.